Business Context and Reporting Period
The supplied filing is a Form 10-K for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. It covers the fiscal year ended December 31, 2020, and was filed March 12, 2021. Selecta is a clinical-stage biotechnology company developing its ImmTOR nanoparticle platform to induce antigen-specific immune tolerance and improve biologic therapies, gene therapies, and autoimmune treatments.
The lead program was SEL-212 for chronic refractory gout, partnered with Swedish Orphan Biovitrum AB (Sobi). Other programs included gene therapy collaborations with AskBio and Sarepta, an IgA nephropathy program, and a preclinical primary biliary cholangitis program.
Key Financial Metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Grant and collaboration revenue | $16.6 million | $6.7 million | Up 149% |
| Research and development expense | $54.5 million | $42.7 million | Up 28% |
| General and administrative expense | $18.9 million | $16.4 million | Up 15% |
| Loss from operations | $56.8 million | $52.5 million | Higher loss |
| Net loss | $68.9 million | $55.4 million | Higher loss |
| Basic and diluted loss per share | $0.68 loss | $1.22 loss | Improved per share |
| Cash, cash equivalents and restricted cash | $140.1 million | $91.6 million | Up $48.5 million |
There were no product sales; all revenue was from collaborations and grants. The implied operating margin was approximately negative 342%, and the net margin was approximately negative 415%, reflecting the company’s development-stage status and limited revenue base.
Operating cash flow was $34.9 million provided, compared with $51.4 million used in 2019. The positive 2020 amount was primarily driven by a $94.5 million increase in deferred revenue, rather than recurring operating profitability. Investing cash flow was $0.7 million used, principally for property and equipment. Financing cash flow was $14.4 million provided.
At December 31, 2020, total assets were $165.4 million, total liabilities were $183.4 million, and stockholders’ deficit was $18.0 million. The company had $25.0 million of outstanding principal under its 2020 term loan, with an additional $10.0 million potentially available subject to milestone and lender conditions. Warrant liabilities were $28.7 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased by $9.9 million, primarily from the Sobi license, clinical supply shipments, and reimbursement of SEL-212 Phase 3 development costs.
- Research and development expense rose $11.8 million due mainly to the SEL-212 DISSOLVE Phase 3 program, the COMPARE trial, and the AskBio collaboration.
- Net loss increased $13.5 million, driven partly by higher operating expenses and a $10.4 million non-cash increase in the fair value of warrant liabilities.
- Cash increased by $48.5 million, largely because of deferred revenue recognized as a liability, the Sobi transaction, and new debt financing.
- The company entered into the Sobi License in June 2020. Sobi paid a $75.0 million upfront fee, purchased $25.0 million of common stock, agreed to fund the SEL-212 Phase 3 program, and provided potential milestone payments of up to $630.0 million plus tiered royalties.
- The company entered into a $35.0 million term-loan facility in August 2020. The $25.0 million Term A Loan was funded and used partly to repay the prior term loan; the $10.0 million Term B Loan remained conditional.
- Deferred revenue increased to $110.8 million at year-end from $16.4 million, reflecting upfront and other collaboration consideration that had not yet been recognized as revenue.
Guidance, Outlook, Risks and Unusual Items
- Management expected Phase 3 DISSOLVE enrollment to be completed in the second half of 2021 and topline data in the second half of 2022.
- The company expected to initiate the MMA-101 Phase 1/2 program in the first half of 2021 and report preliminary data by the end of 2021. The SEL-399 clinical trial was expected to produce topline results in the fourth quarter of 2021.
- Management stated that cash, cash equivalents, and restricted cash at December 31, 2020 were expected to fund operating expenses and capital requirements into the second quarter of 2023, but cautioned that this estimate depended on assumptions that could prove incorrect.
- The company expects continuing operating losses and requires substantial additional funding. Potential funding sources include equity offerings, debt, collaboration payments, licensing transactions, and grants.
- COVID-19 could delay clinical enrollment, site operations, regulatory interactions, manufacturing, supply chains, and the launch or completion of clinical programs. Management reported no material impact on clinical programs as of the filing date but noted substantial uncertainty.
- SEL-212 did not achieve statistical superiority over pegloticase on the primary endpoint in the Phase 2 COMPARE trial, although it showed statistically significant benefits on certain secondary or subgroup measures. The reported topline results remained subject to full analysis and verification.
- The company relies heavily on third parties, including 3SBio in China for pegadricase and contract manufacturers and research organizations for clinical and manufacturing activities.
- A $10.4 million non-cash warrant-liability charge materially affected 2020 earnings. The warrants were valued using Level 3 Black-Scholes assumptions, including approximately 98.6% expected volatility.
- The company disclosed a stockholder derivative action and a related litigation demand concerning the December 2019 private placement. No liability was accrued because any loss was considered not probable or not estimable.
- The company had no approved products, no product revenue, no declared dividends, and accumulated losses of $404.6 million at year-end.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the source filing is for Selecta Biosciences, Inc. under ticker SELB, while the request identifies Cartesian Therapeutics, Inc.
- Review the full audited financial statements and notes for deferred revenue, collaboration accounting, warrant valuation, debt terms, and liquidity assumptions.
- Verify the final design, enrollment, statistical endpoints, and results of the SEL-212 DISSOLVE Phase 3 trials, including the effect of Sobi’s funding and rights.
- Assess whether the positive operating cash flow is sustainable or primarily reflects upfront collaboration consideration and deferred revenue.
- Evaluate the company’s ability to obtain additional capital before projected cash exhaustion and the potential dilution or restrictions associated with future financings.
- Monitor the conditional $10.0 million Term B Loan, debt covenants, collateral provisions, and potential acceleration upon an event of default.
- Track the outcome of the stockholder litigation related to the December 2019 private placement and any related financial exposure.
- Review manufacturing and supply-chain concentration, particularly dependence on 3SBio and third-party contract manufacturers.
- Consider the impact of remaining warrants, stock options, and other potential dilution; approximately 20.2 million potentially dilutive common shares were excluded from diluted loss per share because they were antidilutive.